- Home
- KNDI vs CHRS Comparison
KNDI vs CHRS Comparison
Compare KNDI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- CHRS
- Stock Information
- Founded
- KNDI 2002
- CHRS 2010
- Country
- KNDI China
- CHRS United States
- Employees
- KNDI N/A
- CHRS N/A
- Industry
- KNDI Auto Manufacturing
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNDI Consumer Discretionary
- CHRS Health Care
- Exchange
- KNDI Nasdaq
- CHRS Nasdaq
- Market Cap
- KNDI 154.6M
- CHRS 185.5M
- IPO Year
- KNDI N/A
- CHRS 2014
- Fundamental
- Price
- KNDI $0.96
- CHRS $1.65
- Analyst Decision
- KNDI
- CHRS Strong Buy
- Analyst Count
- KNDI 0
- CHRS 4
- Target Price
- KNDI N/A
- CHRS $5.38
- AVG Volume (30 Days)
- KNDI 233.9K
- CHRS 10.3M
- Earning Date
- KNDI 11-18-2024
- CHRS 11-06-2024
- Dividend Yield
- KNDI N/A
- CHRS N/A
- EPS Growth
- KNDI N/A
- CHRS N/A
- EPS
- KNDI N/A
- CHRS N/A
- Revenue
- KNDI $118,127,232.00
- CHRS $304,340,000.00
- Revenue This Year
- KNDI N/A
- CHRS $1.64
- Revenue Next Year
- KNDI N/A
- CHRS $16.98
- P/E Ratio
- KNDI N/A
- CHRS N/A
- Revenue Growth
- KNDI N/A
- CHRS 44.19
- 52 Week Low
- KNDI $0.96
- CHRS $0.66
- 52 Week High
- KNDI $3.13
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- KNDI 30.77
- CHRS 67.08
- Support Level
- KNDI $0.97
- CHRS $1.45
- Resistance Level
- KNDI $1.04
- CHRS $1.85
- Average True Range (ATR)
- KNDI 0.07
- CHRS 0.22
- MACD
- KNDI -0.00
- CHRS 0.01
- Stochastic Oscillator
- KNDI 5.00
- CHRS 42.21
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.